PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 9, 2026Anti-Cancer Agents in Medicinal Chemistry0 citations

CAF Heterogeneity and Its Impact on Ovarian Cancer Treatment

CAF Heterogeneity in Ovarian Cancer: Implications for Chemoresistance and Treatment Strategies

View Full Paper

Authors

SGSambasivam GopinathPBPavithra BalakrishnanYMYamini Muli

Discussion

Loading...

Member takes

Overview

Review explores CAF subtypes influencing chemoresistance in ovarian cancer, suggesting new therapeutic strategies.

Key Points

  • This review aims to elucidate the heterogeneous roles of cancer-associated fibroblasts (CAFs) in ovarian cancer and their contribution to chemoresistance.
  • Synthesis of evidence from recent single-cell and proteomic analyses.
  • Delineation of CAF subtypes including myCAFs, iCAFs, and apCAFs.
  • Exploration of the relationship between CAF-mediated pathways and platinum-based chemoresistance.
  • High expression of CAF-associated genes correlates with platinum resistance in ovarian cancer.
  • VCAN enhances ECM stiffness and immune suppression; SULF1 alters ECM sulfation affecting drug uptake.
  • Targeting CAF subtypes may enhance treatment efficacy and improve patient outcomes.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gopinath et al. (2026) studied this question.

synapsesocial.com/papers/69fed008b9154b0b828770d2https://doi.org/10.2174/0118715206434395260409095604
Ask AI
Helpful
Bookmark
Share
View Full Paper